New Antidepressant GLYX-13 (Clinical Trials): Partial NMDA Receptor Agonist
A new antidepressant chemically named “GLYX-13” was developed by the biotech company Naurex for individuals with treatment-resistant depression. It is currently in clinical trials as an anti…
Read article